Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase 1 trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from The University of Texas MD Anderson Cancer Center.